Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Antibody > CD19 > CD9-FM7A1

FITC-Labeled Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63) (0.03% Proclin)

Related Products:

Order Now

  • Source
    Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63) is a mouse monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which provides higher batch consistency and long term security of supply.
  • Application
    Flow Cytometry (Detection the expression of CD19 on Human cells).
  • Clone
    FMC63
  • Species
    Mouse
  • Isotype
    Mouse IgG2a | Mouse kappa
  • Specificity
    This product is a specific antibody specifically reacts with CD19 protein.
  • Reactivity

    Human

  • Immunogen

    Human prolymphocytic leukaemia cell line JVM3.

  • Conjugate

    FITC

    Excitation source: 488 nm spectral line, argon-ion laser

    Excitation Wavelength: 488 nm

    Emission Wavelength: 535 nm

  • Recommended Dilution
    1:50
  • Formulation

    Supplied as 0.2 μm filtered solution in PBS, 0.03% Proclin 300, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Storage

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 12 months under sterile conditions.
Bioactivity-FACS
 CD19 FACS

Flow cytometric analysis of Human peripheral blood lymphocytes staining with FITC-Labeled Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63) (Cat. No. CD9-FM7A1) at 1:50 dilution (2 μL of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100 µL), compared with isotype control antibody. FITC signal was used to evaluate the binding activity (QC tested).

 CD19 FACS

Flow cytometric analysis of Human peripheral blood lymphocytes staining with PE anti-human CD3 antibody and FITC-Labeled Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63) (Cat. No. CD9-FM7A1) at 1:50 dilution (2 μL of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100 µL). FITC signal was used to evaluate the binding activity (QC tested).

  • Background
    FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.
  • Clinical and Translational Updates

Comments (0)

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:12 Details
  • Number of Drugs in Clinical Trials:310 Details
  • Latest Research Phase:NDA/BLA

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message